---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-097582"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T17:44:46.503758+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Corbus Q4 net loss $20.6M; cash $163.3M into 2028; key CRB-701/913 catalysts mid-2026

## Summary
- Q4 2025 net loss $20.6M ($1.25/share) vs $9.5M ($0.78) in Q4 2024; operating expenses rose to $22.0M.
- Cash $163.3M at Dec 31, 2025; extended runway into 2028 after $75M public offering in Q4.
- CRB-701 Phase 1/2 unconfirmed ORR: HNSCC 47.6%, cervical 37.5%; monotherapy data and FDA protocol discussions expected mid-2026.
- CRB-913 Phase 1a: 2.9% placebo-adjusted weight loss at 14 days; Phase 1b CANYON-1 (n=240) results due summer 2026.
- CRB-601 deprioritized; no further patient enrollment. Pipeline updates from ESMO 2025 and SITC 2025.

## SEC filing metadata
- accession: 0001193125-26-097582
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000119312526097582/0001193125-26-097582-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000119312526097582/crbp-20260309.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-097582
- JSON: https://secwatch.observer/filing/0001193125-26-097582.json
- Plain text: https://secwatch.observer/filing/0001193125-26-097582.txt

## Key facts
- Earnings Releases
  Corbus Pharmaceuticals Holdings, Inc. reported fourth quarter and year ended December 31, 2025 results: net income net loss of approximately $20.6 million, or a net loss per basic and diluted share of $1.25, EPS net loss per basic and diluted share of $1.25.
  - Period: fourth quarter and year ended December 31, 2025
  - Net income: net loss of approximately $20.6 million, or a net loss per basic and diluted share of $1.25
  - EPS: net loss per basic and diluted share of $1.25
  - Result: reported results
  source text: The Company reported a net loss of approximately $20.6 million, or a net loss per basic and diluted share of $1.25, for the three months ended December 31, 2025, compared to a net loss of $9.5 million, or a net loss per basic and diluted share of $0.78, for the three months ended December 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595097/000119312526097582/0001193125-26-097582-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.